Emergent Biosolutions

This study looks at 250 people who received the CYFENDUS anthrax vaccine after being exposed to anthrax bacteria. Researchers want to see if the vaccine, given with antibiotics, helps prevent serious anthrax disease. The study will track how many people develop inhalational anthr…

This study looks at how safe and helpful an anthrax treatment called AIGIV is for people with a serious form of anthrax infection. Researchers will follow up to 10 patients who receive AIGIV during an outbreak to see if it reduces deaths and causes any side effects. The goal is t…

This study looks at how well the drug raxibacumab works and how safe it is for people who get sick from breathing in anthrax spores during a mass event, like a bioterrorist attack. Researchers will collect information from up to 100 patients of all ages who receive the drug as pa…

This study will test a drug called AIGIV in people who have inhaled anthrax during a large-scale exposure event. Researchers will track how many patients survive and how the drug affects the body. The goal is to see if AIGIV is safe and helps people recover from this serious infe…

This study will observe up to 10 people in the US who have lab-confirmed anthrax and are treated with the drug raxibacumab. Researchers want to see how well the drug works, including survival rates and side effects, by collecting data from medical records and blood samples. The g…